About Med Group1
Advancing Rapid Diagnostics for Acute Respiratory Infections
Med Group1 is an exclusive U.S. distributor of FebriDx — the only FDA-cleared rapid point-of-care test that simultaneously differentiates bacterial from viral acute respiratory infections using dual biomarkers.
Our mission
Bringing Precision Diagnostics to the Point of Care
Med Group1 partners with healthcare facilities, urgent care networks, and health systems to deploy FebriDx at scale. Our mission is to reduce unnecessary antibiotic prescribing, improve patient outcomes, and lower the total cost of care through actionable, same-visit diagnostic intelligence.
Regulatory status
FDA 510(k) Cleared
FebriDx has received FDA 510(k) clearance for use in patients presenting with acute respiratory infection symptoms. It is indicated for use in CLIA-waived settings, enabling deployment across physician offices, urgent care centers, emergency departments, and retail clinics without the need for a laboratory.
- Acute respiratory infection with fever ≥38°C
- Differentiation of bacterial vs. viral etiology
- Patients ≥2 years of age
- CLIA-waived — no lab required
Dual-biomarker technology
MxA + CRP: Two Biomarkers, One Test
FebriDx simultaneously measures two independent host-response biomarkers from a single fingerstick blood sample, providing a more complete picture of the immune response than any single-biomarker test.
MxA (Myxovirus Resistance Protein A)
MxA is an intracellular protein induced specifically by viral infections via the interferon pathway. Elevated MxA strongly indicates an active viral immune response, helping clinicians avoid unnecessary antibiotic prescribing.
CRP (C-Reactive Protein)
CRP is an acute-phase protein that rises rapidly in response to bacterial infection and inflammation. Elevated CRP in the absence of MxA elevation supports a bacterial etiology and guides antibiotic therapy decisions.
Clinical evidence
Peer-Reviewed Clinical Study Data
FebriDx has been validated in multiple prospective clinical studies published in peer-reviewed journals. Key findings demonstrate high diagnostic accuracy across diverse patient populations.
FebriDx Clinical Validation Study
Sensitivity 87.5% and specificity 97.1% for bacterial infection detection in febrile adults presenting to the emergency department.
Point-of-Care Host Response Testing
FebriDx correctly classified 91% of patients with confirmed viral ARI and 88% with confirmed bacterial ARI, outperforming clinical judgment alone.
Antibiotic Stewardship Impact Study
Implementation of FebriDx in urgent care settings reduced antibiotic prescribing by 38% in patients with confirmed viral ARI without increasing return visits or adverse outcomes.
Clinical indications
Indicated for Four Key Clinical Scenarios
Undifferentiated Febrile Illness
Rapidly triage patients presenting with fever and respiratory symptoms when etiology is unclear, enabling same-visit treatment decisions.
Antibiotic Stewardship
Provide objective evidence to support withholding antibiotics in confirmed viral infections, reducing resistance and adverse drug events.
Influenza-Like Illness (ILI)
Differentiate bacterial co-infection from primary viral ILI during peak respiratory season when rapid, accurate triage is critical.
COVID-19 & Respiratory Viruses
Identify bacterial superinfection in patients with confirmed or suspected viral respiratory illness, including SARS-CoV-2.
Ready to Deploy FebriDx at Your Facility?
Contact our clinical sales team to discuss volume pricing, implementation support, and clinical training for your organization.